• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate).新型化合物 A3IS(Mycosinate)的抗真菌和抗肺囊虫活性。
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0052122. doi: 10.1128/aac.00521-22. Epub 2022 Jul 19.
2
In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates.氟康唑和伏立康唑对非念珠菌酵母及酵母样真菌临床分离株的体外抗真菌活性。
New Microbiol. 2015 Oct;38(4):583-7. Epub 2015 Oct 20.
3
Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.索德菌素:新型抗真菌衍生物对致病性酵母、卡氏肺孢子虫和丝状真菌的体外活性
Antimicrob Agents Chemother. 1998 Nov;42(11):2863-9. doi: 10.1128/AAC.42.11.2863.
4
Erratum for Wiederhold et al., "The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate)".
Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0147522. doi: 10.1128/aac.01475-22. Epub 2023 Jan 16.
5
Investigating the susceptibility profiles and in vitro combinations of caspofungin, itraconazole, fluconazole, voriconazole, clotrimazole, and amphotericin B against clinical isolates causing fungal keratitis.研究卡泊芬净、伊曲康唑、氟康唑、伏立康唑、克霉唑和两性霉素B对引起真菌性角膜炎的临床分离株的药敏谱及体外联合用药情况。
Diagn Microbiol Infect Dis. 2025 Jul;112(3):116806. doi: 10.1016/j.diagmicrobio.2025.116806. Epub 2025 Mar 15.
6
In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.新型抗真菌药物 E1210 对临床重要酵母菌和霉菌的体外活性。
Antimicrob Agents Chemother. 2011 Oct;55(10):4652-8. doi: 10.1128/AAC.00291-11. Epub 2011 Aug 8.
7
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
8
Necessity to identify the causative agent for appropriate treatment in fungal corneal ulcer: an in vitro study.有必要确定真菌性角膜溃疡的病原体,以便进行适当的治疗:一项体外研究。
J Mycol Med. 2018 Mar;28(1):201-205. doi: 10.1016/j.mycmed.2017.07.009. Epub 2018 Feb 2.
9
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.塞来昔布衍生物AR-12在体外具有广谱抗真菌活性,并在新型隐球菌病小鼠模型中增强了氟康唑的活性。
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7115-7127. doi: 10.1128/AAC.01061-16. Print 2016 Dec.
10
Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumonia.雷沙康唑在侵袭性念珠菌病、曲霉病和肺炎预防小鼠模型中的疗效。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01992-20.

本文引用的文献

1
Advances in Antifungal Drug Development: An Up-To-Date Mini Review.抗真菌药物研发进展:最新综述
Pharmaceuticals (Basel). 2021 Dec 16;14(12):1312. doi: 10.3390/ph14121312.
2
Advances in anti-fungal therapies.抗真菌治疗的进展。
Mycopathologia. 2021 Oct;186(5):665-672. doi: 10.1007/s11046-021-00560-2. Epub 2021 Jul 15.
3
Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.在挪威一项为期十二年的回顾性研究中,免疫功能低下的患者感染耶氏肺孢子菌的流行病学和临床特征。
BMC Infect Dis. 2021 Jul 7;21(1):659. doi: 10.1186/s12879-021-06144-1.
4
Revisiting the Role of Biologically Active Natural and Synthetic Compounds as an Intervention to Treat Injured Nerves.重新审视生物活性天然和合成化合物作为治疗受损神经的干预手段的作用。
Mol Neurobiol. 2021 Oct;58(10):4980-4998. doi: 10.1007/s12035-021-02473-z. Epub 2021 Jul 6.
5
Pneumocystis jirovecii: a review with a focus on prevention and treatment.卡氏肺孢子虫:预防与治疗为重点的综述
Expert Opin Pharmacother. 2021 Aug;22(12):1579-1592. doi: 10.1080/14656566.2021.1915989. Epub 2021 Apr 19.
6
Clinical Significance of Manuka and Medical-Grade Honey for Antibiotic-Resistant Infections: A Systematic Review.麦卢卡蜂蜜和医用级蜂蜜对耐抗生素感染的临床意义:一项系统评价
Antibiotics (Basel). 2020 Oct 31;9(11):766. doi: 10.3390/antibiotics9110766.
7
Characterizing the Mechanism of Action of an Ancient Antimicrobial, Manuka Honey, against Pseudomonas aeruginosa Using Modern Transcriptomics.利用现代转录组学表征一种古老抗菌剂麦卢卡蜂蜜对铜绿假单胞菌的作用机制
mSystems. 2020 Jun 30;5(3):e00106-20. doi: 10.1128/mSystems.00106-20.
8
Assessing the individual microbial inhibitory capacity of different sugars against pathogens commonly found in food systems.评估不同糖对食品体系中常见病原体的个体微生物抑制能力。
Lett Appl Microbiol. 2020 Sep;71(3):251-258. doi: 10.1111/lam.13306. Epub 2020 Jun 4.
9
Agastache honey has superior antifungal activity in comparison with important commercial honeys.藿香蜜的抗真菌活性优于重要的商业蜂蜜。
Sci Rep. 2019 Dec 3;9(1):18197. doi: 10.1038/s41598-019-54679-w.
10
Natural products against renin-angiotensin system for antifibrosis therapy.天然产物抗肾素-血管紧张素系统抗纤维化治疗。
Eur J Med Chem. 2019 Oct 1;179:623-633. doi: 10.1016/j.ejmech.2019.06.091. Epub 2019 Jun 29.

新型化合物 A3IS(Mycosinate)的抗真菌和抗肺囊虫活性。

The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate).

机构信息

Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, San Antonio, Texas, USA.

Department of Medicine, The University of Texas Health Science Center, San Antonio, Texas, USA.

出版信息

Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0052122. doi: 10.1128/aac.00521-22. Epub 2022 Jul 19.

DOI:10.1128/aac.00521-22
PMID:35852368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9380569/
Abstract

A3IS (Mycosinate) is a synthetic product which only contains ingredients found naturally within honey. A3IS is a broad-spectrum antimicrobial product which produces a sustained release of hydrogen peroxide at low but therapeutic levels. The product elicits this release through an enzymatic reaction between glucose oxidase and the substrate glucose once the product is hydrated. As medical uses for different honeys are being re-evaluated, the purpose of this study was to evaluate the effects of A3IS against a comprehensive panel of human pathogens, including Pneumocystis species, providing a unique assessment against a panel of eukaryotic pathogens. Without exception, A3IS exhibited significant efficacy at 50% and 100% inhibitory concentrations against a broad spectrum of human pathogens including yeasts, molds (both hyaline and dematiaceous), and dimorphic fungi. Notably, A3IS was effective against fungal strains with a high level of resistance to fluconazole or voriconazole. The 50% inhibitory concentrations for Pneumocystis carinii and P. murina (surrogates for ) were considered "Marked" and "Moderate" on an established rank scale, and would be considered for studies, based on an established pipeline. These results indicate that A3IS is a novel anti-fungal agent against an extensive range of human fungal pathogens.

摘要

A3IS(蜜菌素)是一种合成产品,仅包含天然存在于蜂蜜中的成分。A3IS 是一种广谱抗菌产品,可在低但治疗水平下持续释放过氧化氢。一旦产品水合,葡萄糖氧化酶和基质葡萄糖之间的酶反应就会引发这种释放。随着对不同蜂蜜的医学用途的重新评估,本研究的目的是评估 A3IS 对包括肺孢子菌属在内的全面人体病原体的影响,针对一组独特的真核病原体进行评估。无一例外,A3IS 在 50%和 100%的抑制浓度下对包括酵母、霉菌(透明和暗色)和双相真菌在内的广谱人体病原体均表现出显著的疗效。值得注意的是,A3IS 对具有高水平氟康唑或伏立康唑耐药性的真菌菌株有效。在既定的等级量表上,对卡氏肺孢子虫和鼠肺孢子虫(替代品)的 50%抑制浓度被认为是“显著”和“中度”,并将根据既定的研究管道进行研究。这些结果表明,A3IS 是一种针对广泛的人体真菌病原体的新型抗真菌药物。